PRESS RELEASE
11 NOVEMBER 2026

Mogrify to Present Preclinical Proof-of-Concept Data for First-in-Class Retinal *In Vivo* Reprogramming Therapy

- *Preclinical proof-of-concept data will be presented at the FLORetina-ICOOR 2026 Congress, taking place from 3 - 6 December 2026*
- *Data demonstrate that MOGRIFY-derived transcription factors can preserve and restore functional vision in a rodent model of photoreceptor degeneration*

Cambridge, 11th November 2026: Mogrify Limited (Mogrify®), a regenerative medicine company developing a novel class of *in vivo* reprogramming therapies, today announced it will present preclinical proof-of-concept data at FLORetina-ICOOR 2026. The data support its first-in-class therapy designed to protect and regenerate the retina in patients with retinal disorders.

The company's lead program uses transcription factor-mediated direct reprogramming to convert müller glial cells into functional photoreceptors within the retina. By addressing the photoreceptor loss underlying retinal degeneration, the approach aims to preserve and regenerate retinal function and restore clinically meaningful vision in patients with a range of retinal disorders.

In a recently completed large-scale preclinical proof-of-concept study, Mogrify demonstrated statistically significant preservation and restoration of visual function across multiple functional endpoints in a rodent model of induced retinal degeneration. The study used AAV-delivered combinations of transcription factors identified through the Company's proprietary platform.

Mogrify's platform combines next-generation sequencing and a human gene regulatory network-based approach to systematically and impartially identify optimal transcription factor combinations for controlling human cell fate. The technology enables direct *in vivo* conversion between any source cell type and any target cell type of clinical interest.

Chief Scientific Officer at Mogrify, Dr Jonathan Appleby, will lead the program towards first-in-human studies, bringing 30 years of medicines development expertise. Mogrify is actively seeking partners to support the program's advancement.

Dr. Jonathan Appleby, Chief Scientific Officer, Mogrify, said:

"We are thrilled to have generated statistically robust evidence that AAV delivery of MOGRIFY-identified transcription factor combinations can both protect against and reverse vision loss in a preclinical model of retinal degeneration. Demonstrated across several dosing formats and multiple functional endpoints, these findings represent an important step towards the development of a fundamentally novel and gene-agnostic approach to treating retinal disease."

Joe Foster, Chief Executive Officer, Mogrify, added:

"These results are an exciting milestone, providing a robust foundation for advancing our lead program towards clinical development. We are now exploring licensing and investment opportunities to progress this asset into first-in-human studies"

The presentation, **Delivery of a selected combination of transcription factors can improve visual function in a preclinical model of retinal degeneration**, will be given at the FLORetina-ICOOR 2026 Congress, taking place 3–6 December 2026.

- Presentation Track: IRD 1 – Natural History, Endpoints & Therapies
- Presentation Date: Thursday, 3 December 2026
- Presentation Time: 12:00–13:00

The data will also be presented as part of The Dolphin Tank, EYENOVATE's premier ophthalmology and vision science innovation showcase, hosted during FLORetina-ICOOR 2026.

For further information about partnering with Mogrify, please visit: mogrify.co.uk/investors/

ENDS

Notes to Editors



Dr. Jonathan Appleby
Chief Scientific Officer, Mogrify



Joe Foster
Chief Executive Officer, Mogrify

For high-resolution images please contact Zyme Communications.

For further information please contact:

Mogrify (inquiries)
Mark Cavanagh, Chief of Staff
Tel: + 44 (0) 7875 955 266
Email:mark.cavanagh@mogrify.co.uk

Zyme Communications (media inquiries)
Lorna Cuddon BSc (Hons) ACIM
Tel: +44 (0) 7811 996 942
E-mail:lorna.cuddon@zymecommunications.com

To opt-out from receiving press releases from Zyme Communications please e-mail info@zymecommunications.com. To view our privacy policy, please click here.

About Mogrify www.mogrify.co.uk

Mogrify has developed a proprietary platform technology that combines single-cell sequencing and an advanced computational methodology to effect direct cellular reprogramming (Rackham et al., Nature Genetics, 2016).

The platform, MOGRIFY®, enables systematic and unbiased identification of the optimal transcription factor combinations required to control human cell fate. Deploying next-generation sequencing and a human gene regulatory network-centric approach, the platform uniquely positions the Company to affect direct *in vivo* transdifferentiation between any source cell type and any target cell type of clinical interest.

The Company is currently focused on harnessing its award-winning platform to control cell fate within the retina, with the aim of protecting and regenerating photoreceptor cells and restoring retinal function. Its objective is to develop a clinically feasible *in vivo* reprogramming therapy that acts directly within the retina to treat patients with a range of retinal disorders.

About Dr. Jonathan Appleby, Chief Scientific Officer, Mogrify

Dr Appleby is an accomplished medicines developer, having operated in all phases of therapeutic development from discovery to commercial launch. He joined Mogrify from the Cell and Gene Therapy Catapult, where he was Executive Director and Chief Scientific Officer and led the R&D group focused on ATMP manufacturing processes and analytical development for five years. Prior to this, Dr Appleby was CSO for Cell and Gene Therapy in GSK's Rare Diseases Unit, where he led the team that developed Strimvelis™, the multi-award-winning and first autologous pediatric CD34+ stem cell gene therapy to be approved for commercial use. He also led for 2 years the ARSA gene therapy, which was later out-licensed to Orchard Therapeutics and recently approved as Lenmeldy™.